Lymphoma: Clinical Trials

3,697 trials for Lymphoma, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

1609 completed, 505 terminated, 496 recruiting, 464 unknown. 3697 Phase 2, 974 Phase 1, 77 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 23697Completed 1609, Terminated 505, Recruiting 496, Unknown 464, Active not recruiting 308, Withdrawn 156, Not yet recruiting 141, Suspended 13, Enrolling by invitation 5
Phase 1974Completed 352, Recruiting 162, Terminated 147, Unknown 140, Active not recruiting 74, Withdrawn 59, Not yet recruiting 33, Suspended 6, Enrolling by invitation 1
Phase 377Completed 24, Recruiting 19, Unknown 11, Active not recruiting 8, Not yet recruiting 7, Terminated 6, Withdrawn 2

Follow Lymphoma: new trials by email Literature Review of Lymphoma trials Research Report on Lymphoma

Trials (filtered) newest first · largest first

All 3,697 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Multi-CAR-T Cells Targeting B Cell Lymphomas
4SCAR19 and 4SCAR20/22/70/PSMA/13/79b/GD2 - B Cell Lymphoma (BCL)
Phase 1 / Phase 2Not yet recruitingShenzhen Geno-Immune Medical Institute112027-06-012026-11-02
Prizloncabtagene Autoleucel (Prizlon-cel) for the Treatment of Relapsed or Refractory Large B-cell Lymphoma Post FDA Approved CAR T-cell Therapy
Prizloncabtagene Autoleucel - Large B Cell Lymphoma, LBCL
Phase 2Not yet recruitingAbelZeta Inc.552027-05-012026-10-15
Smart 3: A Multi-Center Phase 2 Trial Of Golcadomide, Glofitamab And Polatuzumab Vedotin (G2P) For Patients With Newly Diagnosed Large B-Cell Lymphoma
golcadomide, Obinutuzumab, Polatuzumab - Multi Center, Phase 2
Phase 2Not yet recruitingM.D. Anderson Cancer Center602027-04-292026-11-05
Polatuzumab Vedotin, Mosunetuzumab, and Acalabrutinib for the Treatment of Mantle Cell Lymphoma, PAcMan Trial
Polatuzumab Vedotin, Acalabrutinib, Mosunetuzumab - Mantle Cell Lymphoma
Phase 2Not yet recruitingUniversity of Washington272027-03-012026-11-02
Randomized Phase 2 Study Of Epcoritamab Vs Watch And Wait InPatients With Previously Untreated Low Tumor Burden FollicularLymphoma
Epcoritamab, Observation - Randomized, Phase 2
Phase 2Not yet recruitingM.D. Anderson Cancer Center402027-02-122026-11-02
Safety and Efficacy of Early Second Infusion of Axi-cel Based on ctDNA for R/R Large B - Cell Lymphoma
Infusion of Axicabtagene Ciloleucel - Relapsed/Refractory Diffuse Large B-cell Lymphoma
Phase 1 / Phase 2RecruitingZhujiang Hospital152027-02-012025-03-30
IDH1-vac in Patients With Newly Diagnosed IDH1R132H-positive High-grade Astrocytomas
IDH1-vac, IS-vac, Temozolomide (TMZ) - Astrocytoma, IDH-Mutant, Grade 3, Astrocytoma, IDH-Mutant, Grade 4
Phase 2Not yet recruitingGerman Cancer Research Center2162027-02-012026-10-22
Testing the Safety of Anti-Cancer Drug, CX-5461 (Pidnarulex), in Treating Lymphoma With Specific Changes in the MYC Gene
Biopsy Procedure, Biospecimen Collection, Computed Tomography - Burkitt Lymphoma, Double-Expressor Lymphoma
Phase 1 / Phase 2RecruitingNational Cancer Institute (NCI)502027-01-112026-10-14
Ceritinib Treatment for Recurrent Meningiomas
Ceritinib - Recurrent Meningioma, Grade I and Grade II
Phase 2Not yet recruitingKevin Petrecca102027-01-012026-10-23
Early Prophylactic rhTPO Administration for Thrombocytopenia Associated With EAP Regimen-Based Hematopoietic Stem Cell Mobilization
rhTPO prophylaxis plus EAP stem-cell mobilization - Multiple Myeloma (MM), Lymphoma, Large B-Cell, Diffuse (DLBCL), Lymphoma, Hematopoietic Stem Cell Mobilization
Phase 2 / Phase 3Not yet recruitingThe Affiliated People's Hospital of Ningbo University702027-01-012026-09-30
GRACE: A Phase 1/2a Study of VTRU200 in Relapsed/Refractory AML, High-risk MDS, DLBCL Post CART Failure and Advanced Solid Tumors
VTRU200 - Acute Myeloid Leukemia, Diffuse Large B Cell Lymphoma (DLBCL)
Phase 1 / Phase 2Not yet recruitingVitruviae1082027-01-012026-08-06
Depletion of CD45RA Positive Naive T Cells for the Prevention of Graft Versus Host Disease in Older Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia or Myelodysplastic Syndrome
Allogeneic CD34+-enriched and CD45RA-depleted PBSCs, Biospecimen Collection, Bone Marrow Aspiration - Acute Biphenotypic Leukemia, Acute Leukemia
Phase 2Not yet recruitingFred Hutchinson Cancer Center522027-01-012026-09-14
Golidocitinib in Patients With Mycosis Fungoides/Sézary Syndrome and T-Cell Large Granular Lymphocytic Leukemia
Golidocitinib - Mycosis Fungoides/Sezary Syndrome, T-cell Large Granular Lymphocytic Leukemia
Phase 2Not yet recruitingWashington University School of Medicine242026-12-312026-11-05
Phase 2 Trial of CD70.CAR NK Cells for Patients With Primary Refractory or Early Relapsed Diffuse Large B-Cell Lymphoma and Hodgkin Lymphoma
Fludarabine, Cyclophosphamide, CD70.CAR NK Cells - Large B-cell Lymphoma, Hodgkin Lymphoma
Phase 2Not yet recruitingM.D. Anderson Cancer Center1002026-12-282026-07-15
Golcadomide in Combination With Rituximab for the Treatment of Patients With Relapsed or Refractory Mantle Cell Lymphoma
Biopsy Procedure, Biospecimen Collection, Bone Marrow Biopsy - Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma
Phase 1 / Phase 2RecruitingCity of Hope Medical Center582026-12-212026-10-22
Clinical Study of SYS6055 Injection in Participants With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
SYS6055 - Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
Phase 1 / Phase 2Not yet recruitingBeijing Kangchuanglian Biopharmaceutical Technology Research Co., Ltd3842026-12-152026-10-29
A Clinical Trial of MK-1045 With Zilovertamab Vedotin in Participants With Diffuse Large B-cell Lymphoma (MK-1045-010)
MK-1045, Zilovertamab vedotin, Rituximab - Lymphoma, Large B-Cell, Diffuse, Diffuse Large B-Cell Lymphoma
Phase 2 / Phase 3Not yet recruitingMerck Sharp & Dohme LLC4702026-12-132026-11-05
MRD-Adapted Low-Dose Radiation Therapy During Frontline Chemoimmunotherapy for Diffuse Large B-Cell Lymphoma
Low-Dose Radiation Therapy (LDRT), Standard Frontline Chemoimmunotherapy - Diffuse Large B-Cell Lymphoma
Phase 2Not yet recruitingUniversity of Nebraska502026-12-122026-11-06
REGN9220 in Combination With Odronextamab in Adult Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphomas (BCNHLs)
REGN9220, Odronextamab - Diffuse Large B-Cell Lymphoma (DLBCL)
Phase 1 / Phase 2Not yet recruitingRegeneron Pharmaceuticals362026-12-072026-10-21
A Study of Sonrotoclax (BGB-11417) in Children With Relapsed or Refractory Acute Myeloid Leukemia and B-cell Acute Lymphoblastic Leukemia
sonrotoclax, Azacitidine, Inotuzumab ozogamicin - Relapsed Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
Phase 1 / Phase 2Not yet recruitingBeOne Medicines302026-12-012026-10-26

Showing 20 of 3697. Sign in to see all of them.

Narrower conditions

Lymphoma, Non-Hodgkin (1002)  ·  Lymphoma, Large B-Cell, Diffuse (875)  ·  Lymphoma, Follicular (719)  ·  Lymphoma, Mantle-Cell (604)  ·  Hodgkin Disease (590)  ·  Leukemia, Lymphocytic, Chronic, B-Cell (477)  ·  Precursor Cell Lymphoblastic Leukemia-Lymphoma (422)  ·  Burkitt Lymphoma (419)  ·  Lymphoma, B-Cell, Marginal Zone (393)  ·  Leukemia (380)  ·  Recurrence (375)  ·  Lymphoma, B-Cell (329)  ·  Multiple Myeloma (322)  ·  Leukemia, Myeloid, Acute (267)

Broader conditions

Neoplasms by Histologic Type (3681)  ·  Hemic and Lymphatic Diseases (3646)  ·  Immune System Diseases (3614)  ·  Immunoproliferative Disorders (3613)  ·  Lymphatic Diseases (3610)  ·  Lymphoproliferative Disorders (3590)  ·  Neoplasms (3580)  ·  Lymphoma, Non-Hodgkin (1945)  ·  Lymphoma, B-Cell (1140)  ·  Hematologic Diseases (1101)  ·  Pathological Conditions, Signs and Symptoms (925)  ·  Pathologic Processes (903)  ·  Disease Attributes (849)  ·  Leukemia, Lymphoid (741)

Interventions

Rituximab (755)  ·  Cyclophosphamide (639)  ·  Etoposide (309)  ·  Doxorubicin (303)  ·  Vincristine (300)  ·  Prednisone (267)  ·  Cytarabine (205)  ·  Filgrastim (191)  ·  Lenalidomide (190)  ·  fludarabine (181)  ·  fludarabine phosphate (176)  ·  Methotrexate (172)  ·  Dexamethasone (154)  ·  Melphalan (138)  ·  Radiotherapy (136)

Sponsors

National Cancer Institute (NCI) (195)  ·  M.D. Anderson Cancer Center (179)  ·  Memorial Sloan Kettering Cancer Center (95)  ·  Fred Hutchinson Cancer Center (71)  ·  City of Hope Medical Center (51)  ·  Ruijin Hospital (43)  ·  Sun Yat-sen University (42)  ·  Alliance for Clinical Trials in Oncology (38)  ·  Fondazione Italiana Linfomi - ETS (37)  ·  Northwestern University (34)  ·  Hoffmann-La Roche (33)  ·  Masonic Cancer Center, University of Minnesota (33)  ·  University of Washington (32)  ·  Novartis Pharmaceuticals (31)  ·  Chinese PLA General Hospital (30)

Countries

United States (2116)  ·  China (599)  ·  France (302)  ·  Italy (284)  ·  United Kingdom (230)  ·  Germany (226)  ·  Spain (222)  ·  Canada (221)  ·  Australia (171)  ·  South Korea (163)  ·  Belgium (131)  ·  Poland (103)  ·  Netherlands (82)  ·  Japan (81)  ·  Israel (73)

Top investigators

Ajay Gopal (12)  ·  Craig Moskowitz, MD (11)  ·  Brenda Sandmaier (9)  ·  Tanya Trippett, MD (9)

Results publications

PMID 34515338, PMID 41671463, PMID 35622074, PMID 40135712, PMID 40550489, PMID 31401903, PMID 32632956, PMID 32499241, PMID 39319495, PMID 23834234, PMID 34398557, PMID 40802906, PMID 17242396, PMID 21403127, PMID 22430088, PMID 23065508, PMID 23524640, PMID 26373676, PMID 27282998, PMID 30125215, PMID 30620669, PMID 31050355, PMID 32770353, PMID 34780125, PMID 35787017, PMID 35882475, PMID 37981564, PMID 38551807, PMID 40156952, PMID 40472301, PMID 18997171, PMID 19179301, PMID 19451441, PMID 21527516, PMID 22045986, PMID 23753028, PMID 24224624, PMID 24443277, PMID 24652992, PMID 24862638, PMID 25381051, PMID 25795722, PMID 26755709, PMID 27209293, PMID 28054442, PMID 28925994, PMID 28974506, PMID 29437592, PMID 30501490, PMID 30518502

NIH funding

2023 (44), U10CA180820 (40), P30CA015704 (37), P30CA033572 (37), 2015 (30), 2018 (25), U10CA031946 (25), 2017 (24), U10CA032102 (24), U10CA180886 (23), 2014 (22), 2016 (22), U24CA196172 (21), P30CA015083 (20), P30CA016672 (18)